Phibro Animal Health Corporation $PAHC Shares Sold by Wakefield Asset Management LLLP

Wakefield Asset Management LLLP trimmed its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 24.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,328 shares of the company’s stock after selling 12,842 shares during the quarter. Wakefield Asset Management LLLP owned approximately 0.10% of Phibro Animal Health worth $1,591,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Capricorn Fund Managers Ltd purchased a new stake in Phibro Animal Health in the 3rd quarter worth $10,233,000. JPMorgan Chase & Co. increased its stake in shares of Phibro Animal Health by 1,730.9% during the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after purchasing an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in Phibro Animal Health in the 3rd quarter valued at about $8,931,000. Ranger Investment Management L.P. boosted its holdings in Phibro Animal Health by 101.1% in the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after buying an additional 179,975 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Stock Up 3.4%

Shares of NASDAQ:PAHC opened at $50.43 on Wednesday. Phibro Animal Health Corporation has a 52-week low of $16.16 and a 52-week high of $56.30. The stock has a market cap of $2.04 billion, a P/E ratio of 22.41, a PEG ratio of 0.75 and a beta of 0.74. The business has a fifty day moving average of $45.59 and a two-hundred day moving average of $41.95. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million for the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be issued a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s payout ratio is presently 21.33%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PAHC shares. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. Finally, Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $37.50.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20. Following the completion of the sale, the chief executive officer owned 1,480 shares in the company, valued at $79,520.40. This trade represents a 82.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 294,392 shares of company stock valued at $14,056,947. Corporate insiders own 50.13% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.